SLITRK4 and colorectal carcinoma: The targeted suppression of SLITRK4 by lipid–polymer hybrid nanostructures for siRNA delivery significantly decreased liver metastasis, highlighting SLITRK4 as a viable therapeutic target for CRC [237].